POINT Biopharma Global Inc.

NasdaqCM:PNT Voorraadrapport

Marktkapitalisatie: US$1.3b

POINT Biopharma Global Inkomsten in het verleden

Verleden criteriumcontroles 4/6

POINT Biopharma Global has been growing earnings at an average annual rate of 58.2%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 135.4% per year. POINT Biopharma Global's return on equity is 22.8%, and it has net margins of 39.6%.

Belangrijke informatie

58.2%

Groei van de winst

83.5%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei135.4%
Rendement op eigen vermogen22.8%
Nettomarge39.6%
Laatste winstupdate30 Sep 2023

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates

Aug 20
POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Feb 01
We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)

Oct 18
A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)

Point Biopharma plummets on announcing common stock offering

Sep 13

POINT Biopharma Global GAAP EPS of -$0.27 misses by $0.05

Aug 12

Opbrengsten en kosten

Hoe POINT Biopharma Global geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:PNT Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 232449723113
30 Jun 232419721107
31 Mar 23236982096
31 Dec 22227981982
30 Sep 220-791664
30 Jun 220-721656
31 Mar 220-561442
31 Dec 210-461234
30 Sep 210-37928
30 Jun 210-23518
31 Mar 210-18413
31 Dec 200-1349

Kwaliteitswinsten: PNT has high quality earnings.

Groeiende winstmarge: PNT became profitable in the past.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: PNT's earnings have grown significantly by 58.2% per year over the past 5 years.

Versnelling van de groei: PNT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Winst versus industrie: PNT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).


Rendement op eigen vermogen

Hoge ROE: PNT's Return on Equity (22.8%) is considered high.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden